Myelodysplastic syndromes (MDSs) represent clonal hematopoietic stem cell (HSC) disorders in which genetic and/or epigenetic alteration are involved in the normal function of hematopoietic stem and progenitor cells. This results in the development of blood cytopenias and bone marrow dysplasia. In recent years, therapy with hypomethylating agents (HMAs) in combination with supportive therapies is recommended as frontline treatment for patients with high-risk MDSs according to International Prognostic Scoring System (IPSS HR-MDS). Therapy with HMAs is essential namely for IPSS HR-MDS patients who do not proceed to immediate allogeneic stem cell transplantation (al‐ loSCT). For IPSS LR-MDS (International Prognostic Scoring System, low-risk MDSs) patients, however, supportive therapies and growth factors are the mainstay of treatment. Some patients in this group are treated with immunomodulatory agents derived from thalidomide (lenalidomide) or using immunosuppressive therapy (IST). The therapeu‐ tic decisions can change during the course of the disease based on changes in risk- category and the functional status of patients, in response to prior therapies, changes in patient preferences, and other factors. Resistance to chemotherapy is a serious obstacle to the successful treatment of overall malignancies, including AML and MDS. The failure of therapeutic treatment may be due to the development of multidrug resistance (MDR) phenotype. MDR represents the induction of large-scale defensive mechanisms from which the upregulation of membrane transporters (like P-glycoprotein – P-gp) effluxing chemotherapeutic drugs from tumor cells represents the most observed molecular causality. Other mechanisms of MDR include drug metabolism, alterations in drug-induced apoptosis, epigenetic changes, epithelial-mesenchymal transition, alteration in drug targets structures, and acceleration of DNA repair. The present contribution represents a state-of-the-art review of available knowledge about this issue.
Cieľom prieskumu bolo zistenie percepcie rizika nesteroidových antireumatík (NSA) pacientmi. Použili sme metódu dotazníkového zisťovania v súbore 400 náhodne vybraných pacientov, vyhodnotenie metódami deskriptívnej štatistiky. Predložené výsledky preukazujú pestrú paletu názorov, potvrdzujú vysoký záujem respondentov o daný problém, stávajú sa dobrým východiskom pre rozšírenie zisťovania na ďalšie oblasti percepcie rizika užívania liekov. Dostatok informácií o riziku užívania lieku zo strany pacientov a identifikácia krízových momentov percepcie rizika lieku sú nevyhnutným predpokladom skvalitnenia zdravotnej starostlivosti a vzostupu spokojnosti pacienta.
The aim of the survey was to identify the risk perception of nonsteroidal anti-inflammatory drugs (NSAIDs) by patients. We used the method of questionnaire survey of 400 randomly selected patients, evaluated by methods of descriptive statistics. The results present a diverse range of views, confirm a high interest of respondents in the problem, and can become a good starting point for extending the survey to other areas of risk perception of medication use. Enough information about the risks of medication use by patients and identification of critical moments in risk perception of medications are prerequisites for improving health care and increasing patient satisfaction.
